IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma
-
Published:2022-06
Issue:
Volume:536
Page:215663
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Fei Keke,
Ni Haiqing,
Zhu Mengjia,
Kuang Zhihui,
Wu Min,
Wu Zhihai,
Wang Feifei,
Zhou Shuaixiang,
Jing Hua,
Wu Weiwei,
Wu Dongdong,
Bai DongmeiORCID,
Chen Bingliang
Subject
Cancer Research,Oncology